Second solid tumors: screening and management guidelines in long-term survivors after allogeneic stem cell transplantation. Semin Hematol 2012 Jan;49(1):4-9
Date
01/10/2012Pubmed ID
22221779DOI
10.1053/j.seminhematol.2011.10.013Scopus ID
2-s2.0-84855409965 (requires institutional sign-in at Scopus site) 25 CitationsAbstract
With greater numbers of patients surviving long-term after allogeneic stem cell transplantation (SCT), second malignancies have increasingly been recognized. Secondary solid tumors, the most prevalent second malignancies after allogeneic SCT, are reviewed with particular emphasis on recent developments in the pathogenesis, early diagnosis, and treatment of these transplant-related complications.
Author List
SociƩ G, Rizzo JDAuthor
J. Douglas Rizzo MD, MS Director, Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Hematopoietic Stem Cell TransplantationHumans
Mass Screening
Neoplasms, Second Primary
Practice Guidelines as Topic
Survivors
Time Factors
Transplantation, Homologous